4 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow Lymphomatous Involvement of Non-Cutaneous Extranodal Site: new trials by email Literature Review of Lymphomatous Involvement of Non-Cutaneous Extranodal Site trials Research Report on Lymphomatous Involvement of Non-Cutaneous Extranodal Site
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
Burkitt Lymphoma (4) · Immunoblastic Lymphadenopathy (4) · Intraocular Lymphoma (4) · Leukemia, Hairy Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, T-Cell (4) · Lymphoma, T-Cell, Cutaneous (4) · Mycosis Fungoides (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)
Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Chronic Disease (4) · DNA Virus Infections (4) · Disease Attributes (4) · Epstein-Barr Virus Infections (4) · Eye Neoplasms (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Herpesviridae Infections (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Infections (4)
Bendamustine Hydrochloride (1) · Dasatinib (1) · Lenalidomide (1) · MLN 8237 (1) · Rituximab (1) · Vorinostat (1) · veliparib (1)
National Cancer Institute (NCI) (4)
United States (4)
John Gerecitano (1) · John Sarantopoulos (1) · Leslie Andritsos (1) · Tanya Siddiqi (1)
P30CA008748 (1), P30CA016058 (1), P30CA033572 (1), U01CA062505 (1), U01CA069856 (1), U01CA076576 (1), U10CA032102 (1), U10CA180888 (1), UM1CA186717 (1)